Phaseline

Targets › OTOF

OTOF (Otoferlin): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 3 Phase 1, 1 Phase 3; Neurology, Other; next expected readout Jul 2027.

Key calcium ion sensor involved in the Ca(2+)-triggered synaptic vesicle-plasma membrane fusion and in the control of neurotransmitter release at these output synapses. Interacts in a calcium-dependent manner to the presynaptic SNARE proteins at ribbon synapses of cochlear inner hair cells (IHCs) to trigger exocytosis of neurotransmitter. (UniProt, Q9HC10)

Open in Phaseline: the race on OTOF, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eli LillyAAVAnc80-hOTOF
Adeno-associated virus serotype delivering functional otoferlin gene
OTOFPhase 3Sensorineural Hearing Loss, BilateralOct 2028
SensorionSENS-501
Gene therapy for OTOF mutations
OTOFPhase 1OTOF Gene MutationJul 2027
Shanghai Euhearing TherapeuticsEHT102 Injection
Dual-vector gene therapy for OTOF gene replacement
OTOFPhase 1Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)Jun 2028
Regeneron PharmaceuticalsDB-OTO
AAV-mediated otoferlin gene delivery
OTOFPhase 1Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)Feb 2029

Conditions

Sensorineural Hearing Loss, Bilateral (1) Treatment of Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) (1) Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF) (1) OTOF Gene Mutation (1)

Modalities

other (2), small molecule (2)

Companies

Eli Lilly (1) Shanghai Euhearing Therapeutics (1) Regeneron Pharmaceuticals (1) Sensorion (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.